مصطلحات الفهرس: aged, article, bullous pemphigoid/dt [Drug Therapy], cancer combination chemotherapy, child, comorbidity, controlled study, Cytomegalovirus, cytomegalovirus infection/di [Diagnosis], cytomegalovirus infection/dt [Drug Therapy], cytomegalovirus infection/th [Therapy], diagnostic test accuracy study, diffuse large B cell lymphoma/dt [Drug Therapy], female, human, immunocompromised patient, immunosuppressive treatment, incidental finding, infant, liver failure/dt [Drug Therapy], liver failure/su [Surgery], liver transplantation, lupus erythematosus nephritis/dt [Drug Therapy], major clinical study, male, medical record review, middle aged, mouth ulcer, mucus, multiplex polymerase chain reaction, newborn, outcome assessment, palliative therapy, pathologist, pemphigus vulgaris/dt [Drug Therapy], predictive value, preschool child, priority journal, retrospective study, rheumatoid arthritis/dt [Drug Therapy], school child, prednisolone/dt [Drug Therapy], valganciclovir/dt [Drug Therapy], polymerase chain reaction system, mucosal swab, 2012-15 AusDiagnostics Easy-Plex 12-well assay, 2015-16 AusDiagnostics High-Plex Herpes, Enterovirus and Adenovirus 16-well assay, antiviral therapy, skin biopsy, skin injury, smear, statistically significant result, systemic disease, T cell lymphoma/dt [Drug Therapy], very elderly, virus detection, young adult, azathioprine/dt [Drug Therapy], mycophenolic acid/dt [Drug Therapy], cyclophosphamide plus doxorubicin plus etoposide plus prednisolone plus rituximab plus vincristine/dt [Drug Therapy], cyclophosphamide plus doxorubicin plus prednisolone plus rituximab plus vincristine/dt [Drug Therapy], ganciclovir/dt [Drug Therapy], ganciclovir/iv [Intravenous Drug Administration], methotrexate/dt [Drug Therapy], adolescent, adult, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29260Test
Pathology
LibKey Link

مصطلحات الفهرس: leukopenia/si [Side Effect], low drug dose, lupus erythematosus nephritis/dt [Drug Therapy], lupus erythematosus nephritis/th [Therapy], maintenance therapy, malignant neoplasm/si [Side Effect], menstrual irregularity/si [Side Effect], morning dosage, multiple cycle treatment, nausea/si [Side Effect], ovary insufficiency/si [Side Effect], plasma exchange, priority journal, proteinuria, randomized controlled trial (topic), relapse, remission, review, SLEDAI, systematic review, vomiting/si [Side Effect], abatacept/ae [Adverse Drug Reaction], abatacept/ct [Clinical Trial], abatacept/cb [Drug Combination], abatacept/cm [Drug Comparison], abatacept/dt [Drug Therapy], atacicept/ct [Clinical Trial], atacicept/cb [Drug Combination], atacicept/cm [Drug Comparison], atacicept/dt [Drug Therapy], azathioprine/ae [Adverse Drug Reaction], azathioprine/ct [Clinical Trial], azathioprine/cb [Drug Combination], azathioprine/cm [Drug Comparison], azathioprine/dt [Drug Therapy], azathioprine/po [Oral Drug Administration], calcineurin inhibitor/ae [Adverse Drug Reaction], calcineurin inhibitor/ct [Clinical Trial], calcineurin inhibitor/cb [Drug Combination], calcineurin inhibitor/cm [Drug Comparison], calcineurin inhibitor/dt [Drug Therapy], corticosteroid/ae [Adverse Drug Reaction], corticosteroid/ct [Clinical Trial], corticosteroid/ad [Drug Administration], corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], corticosteroid/iv [Intravenous Drug Administration], corticosteroid/po [Oral Drug Administration], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], cyclophosphamide/ad [Drug Administration], cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], cyclophosphamide/po [Oral Drug Administration], cyclosporine/ct [Clinical Trial], cyclosporine/cb [Drug Combination], cyclosporine/cm [Drug Comparison], cyclosporine/dt [Drug Therapy], cyclosporine/po [Oral Drug Administration], glucocorticoid/cb [Drug Combination], glucocorticoid/dt [Drug Therapy], glucocorticoid/po [Oral Drug Administration], immunoglobulin/ct [Clinical Trial], immunoglobulin/cm [Drug Comparison], immunoglobulin/dt [Drug Therapy], immunoglobulin/iv [Intravenous Drug Administration], immunosuppressive agent/ct [Clinical Trial], immunosuppressive agent/cb [Drug Combination], immunosuppressive agent/cm [Drug Comparison], immunosuppressive agent/dt [Drug Therapy], immunosuppressive agent/sc [Subcutaneous Drug Administration], laquinimod/ct [Clinical Trial], laquinimod/cb [Drug Combination], laquinimod/cm [Drug Comparison], laquinimod/dt [Drug Therapy], laquinimod/po [Oral Drug Administration], leflunomide/ct [Clinical Trial], leflunomide/cb [Drug Combination], leflunomide/cm [Drug Comparison], leflunomide/dt [Drug Therapy], leflunomide/po [Oral Drug Administration], methylprednisolone/ct [Clinical Trial], methylprednisolone/cb [Drug Combination], methylprednisolone/cm [Drug Comparison], methylprednisolone/dt [Drug Therapy], methylprednisolone/iv [Intravenous Drug Administration], misoprostol/ct [Clinical Trial], misoprostol/cb [Drug Combination], misoprostol/cm [Drug Comparison], misoprostol/dt [Drug Therapy], misoprostol/po [Oral Drug Administration], mycophenolate mofetil/ae [Adverse Drug Reaction], mycophenolate mofetil/ct [Clinical Trial], mycophenolate mofetil/cb [Drug Combination], mycophenolate mofetil/cm [Drug Comparison], mycophenolate mofetil/dt [Drug Therapy], mycophenolate mofetil/po [Oral Drug Administration], mycophenolic acid/ct [Clinical Trial], mycophenolic acid/cb [Drug Combination], mycophenolic acid/dt [Drug Therapy], ocrelizumab/ae [Adverse Drug Reaction], ocrelizumab/ct [Clinical Trial], ocrelizumab/cb [Drug Combination], ocrelizumab/cm [Drug Comparison], ocrelizumab/dt [Drug Therapy], placebo, prednisolone/ct [Clinical Trial], prednisolone/cb [Drug Combination], prednisolone/cm [Drug Comparison], prednisolone/dt [Drug Therapy], prednisolone/po [Oral Drug Administration], prednisone/ae [Adverse Drug Reaction], prednisone/ct [Clinical Trial], prednisone/cb [Drug Combination], prednisone/cm [Drug Comparison], prednisone/dt [Drug Therapy], prednisone/po [Oral Drug Administration], rituximab/ae [Adverse Drug Reaction], rituximab/ct [Clinical Trial], rituximab/cb [Drug Combination], rituximab/cm [Drug Comparison], rituximab/dt [Drug Therapy], sirukumab/ae [Adverse Drug Reaction], sirukumab/ct [Clinical Trial], sirukumab/cb [Drug Combination], sirukumab/cm [Drug Comparison], sirukumab/dt [Drug Therapy], sirukumab/iv [Intravenous Drug Administration], tacrolimus/ae [Adverse Drug Reaction], tacrolimus/ct [Clinical Trial], tacrolimus/cb [Drug Combination], tacrolimus/cm [Drug Comparison], tacrolimus/dt [Drug Therapy], tacrolimus/po [Oral Drug Administration], unclassified drug, voclosporin/ct [Clinical Trial], voclosporin/cb [Drug Combination], voclosporin/cm [Drug Comparison], voclosporin/dt [Drug Therapy], AMG 811/ct [Clinical Trial], AMG 811/cm [Drug Comparison], AMG 811/sc [Subcutaneous Drug Administration], AMG 811/dt [Drug Therapy], all cause mortality, alopecia/si [Side Effect], biological therapy, bladder disease/si [Side Effect], bone disease/si [Side Effect], creatinine blood level, creatinine clearance, diarrhea/si [Side Effect], disease activity, dosage schedule comparison, drug dose comparison, drug dose increase, drug dose reduction, drug dose titration, drug megadose, drug withdrawal, end stage renal disease, gastrointestinal symptom/si [Side Effect], herpes zoster/si [Side Effect], human, immunoadsorption, immunosuppressive treatment, infection/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37602Test
Cochrane Database of Systematic Reviews
Click here for full text options
LibKey Link

مصطلحات الفهرس: leukopenia/si [Side Effect], low drug dose, lupus erythematosus nephritis/dt [Drug Therapy], lupus erythematosus nephritis/th [Therapy], maintenance therapy, malignant neoplasm/si [Side Effect], menstrual irregularity/si [Side Effect], morning dosage, multiple cycle treatment, nausea/si [Side Effect], ovary insufficiency/si [Side Effect], plasma exchange, priority journal, proteinuria, randomized controlled trial (topic), relapse, remission, review, SLEDAI, systematic review, vomiting/si [Side Effect], abatacept/ae [Adverse Drug Reaction], abatacept/ct [Clinical Trial], abatacept/cb [Drug Combination], abatacept/cm [Drug Comparison], abatacept/dt [Drug Therapy], atacicept/ct [Clinical Trial], atacicept/cb [Drug Combination], atacicept/cm [Drug Comparison], atacicept/dt [Drug Therapy], azathioprine/ae [Adverse Drug Reaction], azathioprine/ct [Clinical Trial], azathioprine/cb [Drug Combination], azathioprine/cm [Drug Comparison], azathioprine/dt [Drug Therapy], azathioprine/po [Oral Drug Administration], calcineurin inhibitor/ae [Adverse Drug Reaction], calcineurin inhibitor/ct [Clinical Trial], calcineurin inhibitor/cb [Drug Combination], calcineurin inhibitor/cm [Drug Comparison], calcineurin inhibitor/dt [Drug Therapy], corticosteroid/ae [Adverse Drug Reaction], corticosteroid/ct [Clinical Trial], corticosteroid/ad [Drug Administration], corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], corticosteroid/iv [Intravenous Drug Administration], corticosteroid/po [Oral Drug Administration], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], cyclophosphamide/ad [Drug Administration], cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], cyclophosphamide/po [Oral Drug Administration], cyclosporine/ct [Clinical Trial], cyclosporine/cb [Drug Combination], cyclosporine/cm [Drug Comparison], cyclosporine/dt [Drug Therapy], cyclosporine/po [Oral Drug Administration], glucocorticoid/cb [Drug Combination], glucocorticoid/dt [Drug Therapy], glucocorticoid/po [Oral Drug Administration], immunoglobulin/ct [Clinical Trial], immunoglobulin/cm [Drug Comparison], immunoglobulin/dt [Drug Therapy], immunoglobulin/iv [Intravenous Drug Administration], immunosuppressive agent/ct [Clinical Trial], immunosuppressive agent/cb [Drug Combination], immunosuppressive agent/cm [Drug Comparison], immunosuppressive agent/dt [Drug Therapy], immunosuppressive agent/sc [Subcutaneous Drug Administration], laquinimod/ct [Clinical Trial], laquinimod/cb [Drug Combination], laquinimod/cm [Drug Comparison], laquinimod/dt [Drug Therapy], laquinimod/po [Oral Drug Administration], leflunomide/ct [Clinical Trial], leflunomide/cb [Drug Combination], leflunomide/cm [Drug Comparison], leflunomide/dt [Drug Therapy], leflunomide/po [Oral Drug Administration], methylprednisolone/ct [Clinical Trial], methylprednisolone/cb [Drug Combination], methylprednisolone/cm [Drug Comparison], methylprednisolone/dt [Drug Therapy], methylprednisolone/iv [Intravenous Drug Administration], misoprostol/ct [Clinical Trial], misoprostol/cb [Drug Combination], misoprostol/cm [Drug Comparison], misoprostol/dt [Drug Therapy], misoprostol/po [Oral Drug Administration], mycophenolate mofetil/ae [Adverse Drug Reaction], mycophenolate mofetil/ct [Clinical Trial], mycophenolate mofetil/cb [Drug Combination], mycophenolate mofetil/cm [Drug Comparison], mycophenolate mofetil/dt [Drug Therapy], mycophenolate mofetil/po [Oral Drug Administration], mycophenolic acid/ct [Clinical Trial], mycophenolic acid/cb [Drug Combination], mycophenolic acid/dt [Drug Therapy], ocrelizumab/ae [Adverse Drug Reaction], ocrelizumab/ct [Clinical Trial], ocrelizumab/cb [Drug Combination], ocrelizumab/cm [Drug Comparison], ocrelizumab/dt [Drug Therapy], placebo, prednisolone/ct [Clinical Trial], prednisolone/cb [Drug Combination], prednisolone/cm [Drug Comparison], prednisolone/dt [Drug Therapy], prednisolone/po [Oral Drug Administration], prednisone/ae [Adverse Drug Reaction], prednisone/ct [Clinical Trial], prednisone/cb [Drug Combination], prednisone/cm [Drug Comparison], prednisone/dt [Drug Therapy], prednisone/po [Oral Drug Administration], rituximab/ae [Adverse Drug Reaction], rituximab/ct [Clinical Trial], rituximab/cb [Drug Combination], rituximab/cm [Drug Comparison], rituximab/dt [Drug Therapy], sirukumab/ae [Adverse Drug Reaction], sirukumab/ct [Clinical Trial], sirukumab/cb [Drug Combination], sirukumab/cm [Drug Comparison], sirukumab/dt [Drug Therapy], sirukumab/iv [Intravenous Drug Administration], tacrolimus/ae [Adverse Drug Reaction], tacrolimus/ct [Clinical Trial], tacrolimus/cb [Drug Combination], tacrolimus/cm [Drug Comparison], tacrolimus/dt [Drug Therapy], tacrolimus/po [Oral Drug Administration], unclassified drug, voclosporin/ct [Clinical Trial], voclosporin/cb [Drug Combination], voclosporin/cm [Drug Comparison], voclosporin/dt [Drug Therapy], AMG 811/ct [Clinical Trial], AMG 811/cm [Drug Comparison], AMG 811/sc [Subcutaneous Drug Administration], AMG 811/dt [Drug Therapy], all cause mortality, alopecia/si [Side Effect], biological therapy, bladder disease/si [Side Effect], bone disease/si [Side Effect], creatinine blood level, creatinine clearance, diarrhea/si [Side Effect], disease activity, dosage schedule comparison, drug dose comparison, drug dose increase, drug dose reduction, drug dose titration, drug megadose, drug withdrawal, end stage renal disease, gastrointestinal symptom/si [Side Effect], herpes zoster/si [Side Effect], human, immunoadsorption, immunosuppressive treatment, infection/si [Side Effect], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37602Test
Cochrane Database of Systematic Reviews
Click here for full text options
LibKey Link

مصطلحات الفهرس: lupus erythematosus nephritis/co [Complication], lupus erythematosus nephritis/dt [Drug Therapy], major clinical study, male, priority journal, SLEDAI, systemic lupus erythematosus/dt [Drug Therapy], azathioprine/ae [Adverse Drug Reaction], azathioprine/dt [Drug Therapy], azathioprine/to [Drug Toxicity], cyclophosphamide/dt [Drug Therapy], double stranded DNA antibody/ec [Endogenous Compound], glucocorticoid/dt [Drug Therapy], hydroxychloroquine/dt [Drug Therapy], methotrexate/dt [Drug Therapy], mycophenolate mofetil/dt [Drug Therapy], prednisolone/dt [Drug Therapy], rituximab/dt [Drug Therapy], musculoskeletal disease assessment, adult, article, cohort analysis, controlled study, corticosteroid therapy, drug substitution, drug treatment failure, drug use, drug withdrawal, female, human, laboratory test, leukopenia/si [Side Effect], longitudinal study, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/41072Test
LibKey Link

مصطلحات الفهرس: priority journal, protein expression, proteinuria, regulatory T lymphocyte, skin defect, spleen, survival, Th1 cell, Th17 cell, urinary excretion, CCL1 chemokine/ec [Endogenous Compound], CD19 antigen/ec [Endogenous Compound], CD4 antigen/ec [Endogenous Compound], CD5 antigen/ec [Endogenous Compound], complement component C3/ec [Endogenous Compound], CXCL1 chemokine/ec [Endogenous Compound], CXCL2 chemokine/ec [Endogenous Compound], CXCL9 chemokine/ec [Endogenous Compound], DNA antibody, gamma interferon inducible protein 10/ec [Endogenous Compound], immunoglobulin/ec [Endogenous Compound], intercellular adhesion molecule 1/ec [Endogenous Compound], interleukin 10/ec [Endogenous Compound], interleukin 12p40/ec [Endogenous Compound], interleukin 17/ec [Endogenous Compound], interleukin 1beta/ec [Endogenous Compound], interleukin 2 receptor alpha/ec [Endogenous Compound], kidney injury molecule 1/ec [Endogenous Compound], macrophage inflammatory protein 3alpha/ec [Endogenous Compound], messenger RNA/ec [Endogenous Compound], monoclonal antibody/dt [Drug Therapy], monoclonal antibody/ip [Intraperitoneal Drug Administration], retinoid related orphan receptor gamma/ec [Endogenous Compound], transcription factor GATA 3/ec [Endogenous Compound], tumor necrosis factor/ec [Endogenous Compound], unclassified drug, rmt 1 10/dt [Drug Therapy], rmt 1 10/ip [Intraperitoneal Drug Administration], transcription factor FOXP3/ec [Endogenous Compound], animal experiment, animal tissue, antibody blood level, article, B lymphocyte, cell proliferation, controlled study, cytokine production, female, fluorescence activated cell sorting, kidney, kidney disease, kidney function, leukocyte, lupus erythematosus nephritis/dt [Drug Therapy], lymphadenopathy, mouse, nonhuman, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/41997Test
American Journal of Physiology - Renal Physiology
Click here for full text options
LibKey Link

مصطلحات الفهرس: nonhuman, priority journal, protein expression, review, systemic lupus erythematosus, T lymphocyte, Th1 cell, belimumab/dt [Drug Therapy], double stranded DNA/ec [Endogenous Compound], immunoglobulin/ec [Endogenous Compound], mycophenolic acid 2 morpholinoethyl ester/dt [Drug Therapy], T lymphocyte receptor/ec [Endogenous Compound], endothelium cell, antigen specificity, B lymphocyte, CD4+ T lymphocyte, cellular immunity, disease severity, helper cell, human, humoral immunity, immunoreactivity, kidney interstitium, lupus erythematosus nephritis/dt [Drug Therapy], macrophage activation, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28230Test
Click here for full text options
LibKey Link

مصطلحات الفهرس: enteric coated tablet, fracture/si [Side Effect], gastrointestinal symptom/si [Side Effect], herpes zoster/si [Side Effect], human, immunosuppressive treatment, incidence, kidney failure/si [Side Effect], leukopenia/si [Side Effect], lupus erythematosus nephritis/dt [Drug Therapy], maintenance therapy, Medline, ovary insufficiency/si [Side Effect], phase 1 clinical trial (topic), plasmapheresis, proliferative glomerulonephritis, proteinuria/si [Side Effect], randomized controlled trial (topic), relapse/pc [Prevention], relapse/si [Side Effect], remission, review, risk, side effect/si [Side Effect], single drug dose, systematic review, systemic lupus erythematosus, urine sediment, vomiting/si [Side Effect], azathioprine/ae [Adverse Drug Reaction], azathioprine/ct [Clinical Trial], azathioprine/cb [Drug Combination], azathioprine/cm [Drug Comparison], azathioprine/dt [Drug Therapy], corticosteroid/ct [Clinical Trial], corticosteroid/dt [Drug Therapy], creatinine/ec [Endogenous Compound], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], cyclophosphamide/ad [Drug Administration], cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], cyclophosphamide/po [Oral Drug Administration], cyclosporin/ae [Adverse Drug Reaction], cyclosporin/ct [Clinical Trial], cyclosporin/cm [Drug Comparison], cyclosporin/dt [Drug Therapy], cyclosporin A/ae [Adverse Drug Reaction], cyclosporin A/ct [Clinical Trial], cyclosporin A/cm [Drug Comparison], cyclosporin A/dt [Drug Therapy], heparin/cb [Drug Combination], heparin/dt [Drug Therapy], immunoglobulin/ct [Clinical Trial], immunoglobulin/cm [Drug Comparison], immunoglobulin/dt [Drug Therapy], immunoglobulin/iv [Intravenous Drug Administration], immunosuppressive agent/ct [Clinical Trial], immunosuppressive agent/dt [Drug Therapy], methylprednisolone/ct [Clinical Trial], methylprednisolone/cm [Drug Comparison], methylprednisolone/dt [Drug Therapy], methylprednisolone/iv [Intravenous Drug Administration], misoprostol/ct [Clinical Trial], misoprostol/cb [Drug Combination], misoprostol/cm [Drug Comparison], misoprostol/dt [Drug Therapy], mycophenolic acid/cb [Drug Combination], mycophenolic acid/dt [Drug Therapy], mycophenolic acid 2 morpholinoethyl ester/ae [Adverse Drug Reaction], mycophenolic acid 2 morpholinoethyl ester/ct [Clinical Trial], mycophenolic acid 2 morpholinoethyl ester/cm [Drug Comparison], mycophenolic acid 2 morpholinoethyl ester/dt [Drug Therapy], rituximab/ct [Clinical Trial], rituximab/cm [Drug Comparison], rituximab/dt [Drug Therapy], steroid/ct [Clinical Trial], steroid/ad [Drug Administration], steroid/cb [Drug Combination], steroid/cm [Drug Comparison], steroid/dt [Drug Therapy], steroid/iv [Intravenous Drug Administration], steroid/po [Oral Drug Administration], tacrolimus/ae [Adverse Drug Reaction], tacrolimus/ct [Clinical Trial], tacrolimus/cm [Drug Comparison], tacrolimus/dt [Drug Therapy], low drug dose, membranous glomerulonephritis, meta analysis, mortality, outcome assessment, alopecia/si [Side Effect], avascular necrosis/si [Side Effect], Cochrane Library, confidence interval, creatinine blood level, creatinine clearance, data extraction, diarrhea/si [Side Effect], disease classification, dosage schedule comparison, drug dose reduction, drug fatality/si [Side Effect], drug megadose, Embase, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/42603Test
Click here for full text options
LibKey Link

مصطلحات الفهرس: nonhuman, pathogenesis, review, rheumatoid arthritis/dt [Drug Therapy], systemic lupus erythematosus/dt [Drug Therapy], systemic lupus erythematosus/et [Etiology], T lymphocyte activation, treatment outcome, treatment response, abatacept/ae [Adverse Drug Reaction], abatacept/ct [Clinical Trial], abatacept/cb [Drug Combination], abatacept/do [Drug Dose], abatacept/dt [Drug Therapy], abatacept/pd [Pharmacology], abatacept/sc [Subcutaneous Drug Administration], azathioprine/cb [Drug Combination], azathioprine/dt [Drug Therapy], CD28 antigen/ec [Endogenous Compound], corticosteroid/cb [Drug Combination], corticosteroid/dt [Drug Therapy], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], HLA B7 antigen/ec [Endogenous Compound], methotrexate/cb [Drug Combination], methotrexate/dt [Drug Therapy], mycophenolic acid 2 morpholinoethyl ester/cb [Drug Combination], mycophenolic acid 2 morpholinoethyl ester/dt [Drug Therapy], immune response, antigen presenting cell, B lymphocyte, disease severity, drug efficacy, drug indication, drug safety, drug treatment failure, human, immunosuppressive treatment, infection/si [Side Effect], loading drug dose, lupus erythematosus nephritis/co [Complication], lupus erythematosus nephritis/dt [Drug Therapy], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28344Test
Click here for full text options
LibKey Link

مصطلحات الفهرس: toll like receptor 9, adaptive immunity, autoimmune disease, autoimmunity, cytokine production, dendritic cell, drug effect, drug targeting, editorial, human, immune response, immunobiology, innate immunity, lupus erythematosus nephritis/dt [Drug Therapy], lupus erythematosus nephritis/et [Etiology], nonhuman, pathogenesis, priority journal, systemic lupus erythematosus/et [Etiology], Th1 cell, Th2 cell, beta interferon/pd [Pharmacology], CpG oligodeoxynucleotide, DNA/dt [Drug Therapy], gamma interferon, interleukin 12p40, interleukin 18, pattern recognition receptor, toll like receptor, unclassified drug, g rich dna/dt [Drug Therapy], Editorial

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/32292Test
Click here for full text options
LibKey Link

مصطلحات الفهرس: glomerulonephritis/dt [Drug Therapy], glomerulonephritis/ep [Epidemiology], glomerulonephritis/et [Etiology], glomerulonephritis/su [Surgery], glomerulonephritis/th [Therapy], glomerulosclerosis/dt [Drug Therapy], glomerulus filtration rate, Goodpasture syndrome/th [Therapy], hematuria, Heymann nephritis, human, hyperlipidemia/dt [Drug Therapy], immune system, immunoglobulin A nephropathy/dt [Drug Therapy], immunosuppressive treatment, infection/si [Side Effect], infection risk, infection sensitivity, inflammation, kidney biopsy, kidney cell, kidney disease, kidney failure/dt [Drug Therapy], cyclophosphamide/po [Oral Drug Administration], kidney transplantation, leukocyte, lung hemorrhage, lupus erythematosus nephritis/dt [Drug Therapy], membranoproliferative glomerulonephritis/dt [Drug Therapy], membranous glomerulonephritis/dt [Drug Therapy], minimal change glomerulonephritis/dt [Drug Therapy], nephrotic syndrome, nonhuman, pathogenesis, plasmapheresis, priority journal, protein restriction, proteinuria/si [Side Effect], rapidly progressive glomerulonephritis/dt [Drug Therapy], rapidly progressive glomerulonephritis/th [Therapy], risk assessment, sex ratio, side effect/si [Side Effect], T cell depletion, treatment outcome, vasculitis/dt [Drug Therapy], angiotensin receptor antagonist/dt [Drug Therapy], antibody/dt [Drug Therapy], dipeptidyl carboxypeptidase inhibitor/dt [Drug Therapy], hirudin/dt [Drug Therapy], hirudin/pd [Pharmacology], imatinib/dt [Drug Therapy], imatinib/pd [Pharmacology], immunosuppressive agent/ae [Adverse Drug Reaction], immunosuppressive agent/dt [Drug Therapy], immunosuppressive agent/iv [Intravenous Drug Administration], antibody/pd [Pharmacology], antilipemic agent/dt [Drug Therapy], azathioprine/ae [Adverse Drug Reaction], azathioprine/dt [Drug Therapy], azathioprine/po [Oral Drug Administration], azathioprine/pd [Pharmacology], CD20 antibody/dt [Drug Therapy], chlorambucil/ae [Adverse Drug Reaction], chlorambucil/dt [Drug Therapy], chlorambucil/po [Oral Drug Administration], chlorambucil/pd [Pharmacology], corticosteroid/ae [Adverse Drug Reaction], corticosteroid/dt [Drug Therapy], corticosteroid/pd [Pharmacology], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], immunosuppressive agent/po [Oral Drug Administration], immunosuppressive agent/pd [Pharmacology], intercellular adhesion molecule 1 antibody/dt [Drug Therapy], intercellular adhesion molecule 1 antibody/pd [Pharmacology], interleukin 1 receptor blocking agent/dt [Drug Therapy], interleukin 1 receptor blocking agent/pd [Pharmacology], interleukin 10/dt [Drug Therapy], interleukin 10/pd [Pharmacology], mycophenolic acid 2 morpholinoethyl ester/ae [Adverse Drug Reaction], mycophenolic acid 2 morpholinoethyl ester/dt [Drug Therapy], mycophenolic acid 2 morpholinoethyl ester/pd [Pharmacology], n(g) nitroarginine methyl ester/dt [Drug Therapy], n(g) nitroarginine methyl ester/pd [Pharmacology], nitric oxide synthase inhibitor/dt [Drug Therapy], nitric oxide synthase inhibitor/pd [Pharmacology], oligonucleotide/dt [Drug Therapy], oligonucleotide/pd [Pharmacology], prednisone/do [Drug Dose], prednisone/dt [Drug Therapy], prednisone/po [Oral Drug Administration], rapamycin/ae [Adverse Drug Reaction], rapamycin/dt [Drug Therapy], rapamycin/pd [Pharmacology], steroid/dt [Drug Therapy], thrombin inhibitor/dt [Drug Therapy], thrombin inhibitor/pd [Pharmacology], unclassified drug, colony stimulating factor receptor antibody/dt [Drug Therapy], colony stimulating factor receptor antibody/pd [Pharmacology], monocyte chemotactic protein 1 antibody/dt [Drug Therapy], monocyte chemotactic protein 1 antibody/pd [Pharmacology], kidney failure/pc [Prevention], cyclophosphamide/pd [Pharmacology], cyclosporin/dt [Drug Therapy], acute kidney failure/si [Side Effect], Alport syndrome, antibody dependent cellular cytotoxicity, blood clotting, cancer susceptibility, cellular immunity, chronic glomerulonephritis, complement system, conference paper, diagnostic procedure, disease association, drug efficacy, drug induced cancer/si [Side Effect], drug safety, Conference Paper

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27330Test
The Lancet
Click here for full text options
LibKey Link